Development and validation of a machine learning model to evaluate survival in patients with newly diagnosed breast cancer with liver metastasis - Report - MDSpire
Advertisement
Development and validation of a machine learning model to evaluate survival in patients with newly diagnosed breast cancer with liver metastasis
Clinical Report: Machine Learning for Predicting Survival in BCLM
Overview
This study developed a prognostic nomogram for patients with newly diagnosed breast cancer and liver metastases, utilizing data from the SEER database. The model demonstrated robust predictive performance, with C-indices of 0.760, 0.740, and 0.787 across training, internal validation, and external validation cohorts, respectively.
Background
Breast cancer liver metastasis (BCLM) presents significant prognostic challenges and is associated with poor survival outcomes. Current staging systems and prognostic models inadequately predict individual survival for patients with BCLM, necessitating the development of more precise predictive tools. This study addresses the need for tailored prognostic models to enhance risk stratification and treatment decision-making in this high-risk population.
Data Highlights
Cohort
C-index
1-year AUC
3-year AUC
5-year AUC
Training
0.760
0.777
0.757
0.764
Internal Validation
0.740
0.755
0.769
0.754
External Validation
0.787
0.727
0.752
0.801
Key Findings
The nomogram incorporates ten prognostic variables including age, tumor size, and receptor status.
The model achieved a C-index of 0.787 in the external validation cohort.
Calibration curves indicated good agreement between predicted and observed survival.
Decision curve analysis confirmed the clinical utility of the nomogram.
The study highlights the limitations of existing prognostic models for BCLM.
Clinical Implications
The developed nomogram may assist clinicians in providing more individualized survival predictions for patients with BCLM. Further validation is necessary to confirm its applicability in clinical settings.
Conclusion
The proposed nomogram demonstrates strong predictive capabilities for survival in patients with breast cancer and liver metastases, warranting further validation for clinical use.
